---
title: "Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294081196.md"
description: "Wedbush analyst David Nierengarten maintained a Buy rating on Kura Oncology (KURA) with a $36 price target. Concurrently, Barclays also upheld a Buy rating for the stock, setting its price target at $28."
datetime: "2026-07-28T14:17:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294081196.md)
  - [en](https://longbridge.com/en/news/294081196.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294081196.md)
---

# Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Kura Oncology, with a price target of $36.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, Apogee Therapeutics, and Abivax SA Sponsored ADR. According to TipRanks, Nierengarten has an average return of 22.1% and a 53.57% success rate on recommended stocks.

In a report released today, Barclays also maintained a Buy rating on the stock with a $28.00 price target.

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)
- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Bank of America Securities Sticks to Their Buy Rating for Kura Oncology (KURA)](https://longbridge.com/en/news/293454564.md)
- [Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial](https://longbridge.com/en/news/293917050.md)
- [Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma](https://longbridge.com/en/news/293940059.md)
- [Kura Oncology updates CEO Troy Wilson severance terms in revised employment agreement](https://longbridge.com/en/news/294265229.md)
- [Kura Oncology Reports 50% Response Rate in RCC Combination Study](https://longbridge.com/en/news/293955319.md)